[G25-20] Osimertinib (locally advanced, unresectable NSCLC) – Addendum to Project A25-03
Last updated 03.07.2025
Project no.:
G25-20
Commission:
Commission awarded on 27.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G25-20
| Project no. | Title | Status |
|---|---|---|
| A25-03 | Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
03.07.2025 A G-BA decision was published.
G-BA documents on this decision